Related Experiment Videos
Investigations on the antitumor effect and mutagenicity of alpha-MSH fragments containing melphalan
H Süli-Vargha1, A Jeney, L Kopper
1Research Group for Peptide Chemistry, Hungarian Academy of Science, Budapest.
Abstract:
alpha-MSH fragments containing melphalan were tested in vivo on L1210 leukemia and on human amelanotic melanoma xenograft in mice and in vitro on human amelanotic melanoma cell lines. The compounds exhibit significant antitumor activity, but no selectivity in targeting of melanoma can be achieved. There is a difference between melphalan and the melphalyl-peptide in their action on protein synthesis. The peptide derivatives also are less mutagenic than melphalan, according to the SCE assay, furnishing further evidence for the positive effect of natural carrier molecules.
Insights
Alpha-melanocyte-stimulating hormone (alpha-MSH) peptide conjugates showed antitumor effects against leukemia and melanoma. However, these novel compounds lacked melanoma-specific targeting and demonstrated reduced mutagenicity compared to melphalan.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Melphalan is a chemotherapy drug used to treat various cancers.
- Alpha-melanocyte-stimulating hormone (alpha-MSH) plays a role in melanocyte function and has been explored for targeted cancer therapy.
Purpose of the Study:
- To evaluate the antitumor activity and selectivity of alpha-MSH fragments conjugated with melphalan.
- To investigate the effects of these novel peptide derivatives on protein synthesis and mutagenicity compared to unconjugated melphalan.
Main Methods:
- In vivo studies using L1210 leukemia and human amelanotic melanoma xenografts in mice.
- In vitro assays on human amelanotic melanoma cell lines.
- Analysis of protein synthesis inhibition.
- Sister Chromatid Exchange (SCE) assay to assess mutagenicity.
Main Results:
- The alpha-MSH-melphalan conjugates demonstrated significant antitumor activity against both leukemia and melanoma models.
- No specific targeting of melanoma cells was observed.
- Differences in the mechanism of action on protein synthesis were noted between melphalan and its peptide derivatives.
- Peptide derivatives exhibited lower mutagenicity than melphalan in the SCE assay.
Conclusions:
- Alpha-MSH conjugation can yield potent antitumor agents with reduced mutagenicity.
- The use of natural carrier molecules like alpha-MSH may enhance the therapeutic profile of cytotoxic drugs.
- Further research is needed to achieve targeted delivery of these conjugates to melanoma.